Efficacy and Safety of Udenafil Once Daily in Patients with Erectile Dysfunction after Bilateral Nerve-Sparing Robot-Assisted Laparoscopic Radical Prostatectomy: A Randomized, Double-Blind, Placebo-Controlled Study

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the efficacy and safety of udenafil 75 mg once daily in patients with erectile dysfunction following bilateral nerve-sparing robot-assisted laparoscopic radical prostatectomy (BNS-RALP).
Materials and Methods: A multi-center, prospective, randomized, controlled, double-blind study was conducted. Among patients with localized prostate cancer with international index of erectile function-erectile function domain (IIEF-EF) score of 18 or higher before BNS-RALP, those who developed postoperative erectile dysfunction (IIEF-EF score 14 or less at 4 weeks after BNS-RALP) were enrolled. Enrolled patients were randomly assigned to the udenafil 75 mg daily group or the placebo group in a 2:1 ratio. Each subject was followed up at 8 weeks (V2), 20 weeks (V3), and 32 weeks (V4) to evaluate the efficacy and safety of udenafil.
Results: In all, 101 patients were screened, of whom 99 were enrolled. Of the 99 patients, 67 were assigned to the experimental group and 32 to the control group. Ten (14.93%) patients in the experimental group and 10 (31.25%) in the control group dropped out of the study. After 32 weeks of treatment, IIEF-EF score of 22 or higher was seen in 36.51% (23/63) of patients in the experimental group and 13.04% (3/23) patients in the control group (p=0.021). The proportion of patients with IIEF-EF improvement of 25% or more compared to the baseline was 82.54% (52/63) in the experimental group and 62.96% (17/27) in the control group (p=0.058).
Conclusions: Udenafil 75 mg once daily after BNS-RALP improved the erectile function without any severe adverse effects.

참고문헌 (Reference)

• 1 Mydlo JH, "Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy" 95 : 843-846, 2005
• 2 Salem EA, "Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction" 7 : 661-669, 2006
• 3 Cho MC, "Udenafil for the treatment of erectile dysfunction" 10 : 341-354, 2014
• 4 Kang SG, "Udenafil : efficacy and tolerability in the management of erectile dysfunction" 5 : 101-110, 2013
• 5 Rabbani F, "Time course of recovery of erectile function after radical retropubic prostatectomy : does anyone recover after 2years?" 7 : 3984-3990, 2010
• 6 Chung E, "Sexual rehabilitation and cancer survivorship : a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors" 10 (10): 102-111, 2013
• 7 Litwin MS, "Sexual function and bother after radical prostatectomy or radiation for prostate cancer : multivariate qualityof-life analysis from CaPSURE. Cancer of the prostate strategic urologic research endeavor" 54 : 503-508, 1999
• 8 King R, "Satisfaction with sex and erection hardness : results of the Asia-Pacific sexual health and overall wellness survey" 23 : 135-141, 2011
• 9 Brock G, "Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy" 170 (170): 1278-1283, 2003
• 10 Chung JH, "Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction : a multicenter, double-blind, placebo controlled trial" 189 : 1006-1013, 2013
• 11 Padma-Nathan H, "Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nervesparing radical prostatectomy" 20 : 479-486, 2008
• 12 Bill-Axelson A, "Radical prostatectomy or watchful waiting in early prostate cancer" 370 : 932-942, 2014
• 13 Salonia A, "Prevention and management of postprostatectomy sexual dysfunctions. Part 1 : choosing the right patient at the right time for the right surgery" 62 : 261-272, 2012
• 14 Salonia A, "Prevention and management of postprostatectomy sexual dysfunctions part 2 : recovery and preservation of erectile function, sexual desire, and orgasmic function" 62 : 273-286, 2012
• 15 Eastham JA, "Predicting an optimal outcome after radical prostatectomy : the trifecta nomogram" 179 : 2207-2210, 2008
• 16 Makhlouf A, "Phosphodiesterase 11 : a brief review of structure, expression and function" 18 : 501-509, 2006
• 17 Sari Motlagh R, "Penile rehabilitation strategy after nerve sparing radical prostatectomy : a systematic review and network meta-analysis of randomized trials" 205 : 1018-1030, 2021
• 18 Nicolai M, "Penile rehabilitation and treatment options for erectile dysfunction following radical prostatectomy and radiotherapy : a systematic review" 8 : 636974-, 2021
• 19 Kouvelas D, "PDE5 inhibitors : in vitro and in vivo pharmacological profile" 15 : 3464-3475, 2009
• 20 Pavlovich CP, "Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy : results of a randomized double-blind trial with placebo" 112 : 844-851, 2013
• 21 Kumar A, "Nerve-sparing robot-assisted radical prostatectomy : current perspectives" 8 : 2-13, 2021
• 22 Robinson JW, "Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma" 54 : 1063-1068, 2002
• 23 Montorsi F, "Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction" 45 : 339-344, 2004
• 24 Bernard B, "Impact of age at diagnosis of de novo metastatic prostate cancer on survival" 126 : 986-993, 2020
• 25 Potosky AL, "Health outcomes after prostatectomy or radiotherapy for prostate cancer : results from the prostate cancer outcomes study" 92 : 1582-1592, 2000
• 26 Mirone V, "Flexible-dose vardenafil in a communitybased population of men affected by erectile dysfunction : a 12-week open-label, multicenter trial" 2 : 842-847, 2005
• 27 Kim TH, "Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy" 28 : 25-30, 2016
• 28 Mulhall JP, "Erectile function rehabilitation in the radical prostatectomy patient" 7 (7): 1687-1698, 2010
• 29 Zhao C, "Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction : results of a multicenter, randomized, double-blind, placebo-controlled trial" 60 : 380-387, 2011
• 30 Paick JS, "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction" 5 : 2672-2680, 2008
• 31 Montorsi F, "Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy : a randomised placebo-controlled study(REACTT)" 65 : 587-596, 2014
• 32 Jo JK, "Effect of starting penile rehabilitation with sildenafil immediately after robot-assisted laparoscopic radical prostatectomy on erectile function recovery : a prospective randomized trial" 199 : 1600-1606, 2018
• 33 Montorsi F, "Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nervesparing radical prostatectomy" 54 : 924-931, 2008
• 34 Cappelleri JC, "Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function" 54 : 346-351, 1999
• 35 Sforza S, "Can we predict the development of symptomatic lymphocele following robot-assisted radical prostatectomy and lymph node dissection? Results from a tertiary referral Centre" 54 : 328-333, 2020
• 36 Reichard C, "Can focal therapy replace radical therapy for prostate cancer? Against focal therapy" 3 : 524-525, 2017
• 37 Schulz KF, "CONSORT 2010 statement : updated guidelines for reporting parallel group randomised trials" 11 : 32-, 2010
• 38 Lee TK, "A systematic review of expanded prostate cancer index composite(EPIC)quality of life after surgery or radiation treatment" 22 : 7599-7606, 2015
• 39 Kim DJ, "A prospective, randomized, placebo-controlled trial of on-demand vs. nightly sildenafil citrate as assessed by Rigiscan and the international index of erectile function" 4 : 27-32, 2016
• 40 Chiles KA, "A double-blind, randomized trial on the efficacy and safety of hyperbaric oxygenation therapy in the preservation of erectile function after radical prostatectomy" 199 : 805-811, 2018